Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Severe thrombocytopenia due to bone marrow failure in children with dyskeratosis congenita does not respond to eltrombopag treatment: case series
Division of Pediatrics, Department of Clinical Science, Intervention and Technology, Karolinska Institutet; Section of Pediatric Hematology, Immunology and HCT, Astrid Lindgren Children's Hospital.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap. Section of Pediatric Hematology and Oncology, Child and Adolescent Medical Center, University Hospital of Umeå, Umeå, Sweden.
Department of Clinical Immunology and Transfusion Medicine, Medical Diagnostics Center, Karolinska University Hospital, Stockholm, Sweden.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap. Section of Pediatric Hematology and Oncology, Child and Adolescent Medical Center, University Hospital of Umeå, Umeå, Sweden.
Visa övriga samt affilieringar
2024 (Engelska)Ingår i: Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, E-ISSN 1536-3678, Vol. 46, nr 1, s. 57-62Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Dyskeratosis congenita is a rare inherited disease with classic cutaneous symptoms, sometimes accompanied with more severe extracutaneous manifestations such as bone marrow failure, which can be lethal. Eltrombopag is an orally available thrombopoietin receptor agonist in clinical use for increasing platelet levels in patients with immune thrombocytopenia and aplastic anemia. Here, 3 pediatric patients with dyskeratosis congenita are presented with varying disease severity, in which off-label eltrombopag treatment had no clinical effect on bone marrow failure. This, in addition to the negative results in a previous case report, supports the preclusion of eltrombopag use in dyskeratosis congenita.

Ort, förlag, år, upplaga, sidor
Wolters Kluwer, 2024. Vol. 46, nr 1, s. 57-62
Nationell ämneskategori
Hematologi
Identifikatorer
URN: urn:nbn:se:umu:diva-219541DOI: 10.1097/MPH.0000000000002775PubMedID: 37885072Scopus ID: 2-s2.0-85181582874OAI: oai:DiVA.org:umu-219541DiVA, id: diva2:1828124
Tillgänglig från: 2024-01-16 Skapad: 2024-01-16 Senast uppdaterad: 2024-01-16Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Borssen, MagnusNilsson, Frans

Sök vidare i DiVA

Av författaren/redaktören
Borssen, MagnusNilsson, Frans
Av organisationen
Institutionen för medicinsk biovetenskap
I samma tidskrift
Journal of Pediatric Hematology/Oncology
Hematologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 16 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf